Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
250.68
+6.14 (2.51%)
At close: Aug 31, 2026, 4:00 PM EDT
250.99
+0.31 (0.12%)
Pre-market: Sep 1, 2026, 5:00 AM EDT
Jazz Pharmaceuticals Employees
Jazz Pharmaceuticals had 2,890 employees as of December 31, 2025. The number of employees increased by 90 or 3.21% compared to the previous year.
Employees
2,890
Change (1Y)
90
Growth (1Y)
3.21%
Revenue / Employee
$1,592,140
Profits / Employee
$325,520
Market Cap
16.27B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,890 | 90 | 3.21% |
| Dec 31, 2024 | 2,800 | 0 | - |
| Dec 31, 2023 | 2,800 | 0 | - |
| Dec 31, 2022 | 2,800 | -400 | -12.50% |
| Dec 31, 2021 | 3,200 | 1,260 | 64.95% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Genmab | 3,119 |
| Bio-Techne | 3,000 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| BridgeBio Pharma | 1,003 |
| Madrigal Pharmaceuticals | 915 |
| Corcept Therapeutics | 730 |
JAZZ News
- 1 day ago - Jazz reports second interim overall survival results for HERIZON-GEA-01 trial - TheFly
- 1 day ago - Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA - PRNewsWire
- 3 days ago - Jazz Pharmaceuticals price target raised to $299 from $277 at RBC Capital - TheFly
- 4 days ago - Jazz Pharmaceuticals prices upsized $1.1B offering of exchangeable senior notes - TheFly
- 5 days ago - Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases - PRNewsWire
- 5 days ago - Jazz Pharmaceuticals price target raised to $281 from $264 at Truist - TheFly
- 5 days ago - Jazz Pharmaceuticals price target raised to $322 from $283 at Morgan Stanley - TheFly
- 5 days ago - Jazz Pharmaceuticals price target raised to $310 from $292 at Needham - TheFly